Dixtal Medical Purchases Novametrix Pulse Oximetry Business from Respironics
08 Octubre 2007 - 10:14AM
PR Newswire (US)
MURRYSVILLE, Pa., Oct. 8 /PRNewswire-FirstCall/ -- Dixtal Medical,
Inc. and Respironics, Inc. (NASDAQ:RESP) announced today that
Dixtal Medical has acquired the Novametrix pulse oximetry product
line from Respironics. This pulse oximetry product line will be
marketed under the Dixtal/Novametrix brand pursuant to Dixtal
Medical's license of the Novametrix name from Respironics.
Novametrix, founded in 1978 and acquired by Respironics in 2002,
established a market-leading position in reusable pulse oximetry
sensor technology and has been marketing its oximetry products for
over 20 years with an emphasis on high performance, cost-effective,
reusable sensors. Dixtal Medical is a subsidiary of Dixtal
Biomedica, an international medical products company based in
Brazil and also established in 1978. Dixtal Biomedica is the market
leader in multi-parameter monitoring products in Brazil. Dixtal
Biomedica and Novametrix have conducted business together for many
years, with Dixtal Biomedica manufacturing and marketing Novametrix
pulse oximetry products for the Brazilian hospital market. After
Respironics' 2002 acquisition of Novametrix Medical Systems,
Respironics integrated the Novametrix pulse oximetry product line
into Respironics' Critical Care business. Respironics later
determined that the Novametrix pulse oximetry product line was not
a core technology for Respironics and made the decision to exit
this line of business and refocus on its core technologies.
Respironics announced its intention to exit the Novametrix pulse
oximetry business in its July 2007 quarterly earnings release
conference call and included the impact of this divestiture in its
guidance. The sale of the Novametrix pulse oximetry business is not
a material transaction for Respironics. The sale of the Novametrix
pulse oximetry business to Dixtal Medical will result in a company
dedicated to the Novametrix pulse oximetry technology continuing to
serve the Novametrix pulse oximetry customer base. Respironics will
continue to market and sell its core multi-parameter monitoring
products that contain pulse oximetry as these multi-parameter
products, such as the NICO2(R), Tidal Wave(R) and CO2SMO(R)
monitors, are not being sold to Dixtal Medical. Dixtal Medical will
initially focus on establishing the Dixtal/Novametrix pulse
oximetry brand products with a customer-centric organization
designed to support the worldwide installed base of hospitals which
are utilizing Novametrix pulse oximetry products. Dixtal Medical
will continue to develop the Dixtal/Novametrix pulse oximetry
products and eventually will import, market, service and support
Dixtal Biomedica multi-parameter monitoring systems for domestic
and worldwide markets. Respironics is a leading developer,
manufacturer and distributor of innovative products and programs
that serve the global sleep and respiratory markets. Focusing on
emerging market needs, the Company is committed to providing valued
solutions to help improve outcomes for patients, clinicians and
healthcare providers. Respironics markets its products in 141
countries and employs over 5,100 associates worldwide. Further
information can be found on the Company's Web site:
http://www.respironics.com/. FORWARD-LOOKING STATEMENT This
document contains forward-looking statements, including statements
relating to, among other things, developments in the healthcare
industry; the success of the Company's marketing, sales, and
promotion programs; future sales, acceptance, and quality of the
Company's products and programs; the results of clinical trials;
the timing and success of new product introductions; new product
development; anticipated cost savings; FDA and other regulatory
requirements, enforcement actions, product recalls or related field
actions; future results from acquisitions and strategic
investments; growth rates in foreign markets; regulations and other
factors affecting operations and sales outside the United States;
foreign currency fluctuations; the effects of a major natural
disaster, cyber-attack or other catastrophic event that results in
the destruction or disruption of any critical business or
information technology systems; customer consolidation and
concentration; increasing price competition and other competitive
factors in the manufacture, distribution, and sale of products;
interest rate fluctuations; expiration of intellectual property
rights; intellectual property and related litigation; other
litigation; future levels of earnings and revenues; the number of
equity awards granted to employees and changes in the Company's
stock price; and third party reimbursement; all of which are
subject to change. Actual results may differ materially from those
described in any forward-looking statements. Additional information
on potential factors that could affect the Company's financial
results are included in the reports filed with the SEC, including
the reports on Form 10-K, 10-Q and 8-K. DATASOURCE: Respironics,
Inc. CONTACT: Dan Bevevino, Vice President & CFO, Respironics,
Inc., +1-724-387-5235; or Joseph A. Vincent, CMA, Executive Vice
President & General Manager, Dixtal Medical, Inc.,
+1-203-269-1112, ext. 226; or Analyst Information, Joe Calabrese,
+1-212-827-3772, or Julie Tu, +1-212-827-3776, both of Financial
Relations Board, for Respironics Web site:
http://www.respironics.com/
Copyright
Respironics (NASDAQ:RESP)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Respironics (NASDAQ:RESP)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024